Lenalidomide Thornton & Ross Ltd.

Lenalidomide, the active ingredient in Lenalidomide Thornton & Ross Ltd., is an immunomodulatory drug presented as an oral formulation for systemic use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma in adult patients, often as part of combination therapy.

GNH USA supplies Lenalidomide Thornton & Ross Ltd. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides secure logistics for regulated markets.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma or lymphoid cells.

Multiple Myeloma: improves survival and disease control when combined with other agents. Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and corrects cytopenias. Mantle Cell Lymphoma: contributes to response rates in relapsed or refractory disease.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness or lack of energy. - Diarrhea: loose stools, sometimes accompanied by abdominal cramping. - Rash: mild skin erythema or itching. - Neutropenia: reduced neutrophil count, increasing infection risk.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

When prescribing Lenalidomide, clinicians should observe several safety considerations. - Pregnancy risk: contraindicated in pregnancy (Category X); effective contraception required for both patient and partner. - Thromboembolism prophylaxis: assess need for anticoagulation in patients with additional risk factors. - Renal impairment: dose adjustment may be necessary in patients with reduced kidney function. - Hematologic monitoring: regular blood counts to detect neutropenia, anemia or thrombocytopenia. - Drug interactions: review concomitant medications, especially CYP3A4 inducers or inhibitors. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce plasma concentrations. - Anticoagulants (warfarin, direct oral anticoagulants): increased risk of bleeding when combined with thrombocytopenia. - Immunosuppressants (e.g., cyclosporine): heightened risk of severe neutropenia.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase exposure modestly. - P-glycoprotein substrates (e.g., digoxin): potential for altered levels. - Vaccines: live attenuated vaccines may be less effective; avoid during therapy.